Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma.
Takada H, Kurosaki M, Tsuchiya K, Komiyama Y, Itakura J, Takahashi Y, Nakanishi H, Yasui Y, Tamaki N, Maeyashiki C, Kaneko S, Takaura K, Higuchi M, Okada M, Wang W, Osawa L, Sekiguchi S, Hayakawa Y, Yamashita K, Enomoto N, Izumi N. Takada H, et al. Among authors: okada m. Cancers (Basel). 2019 Aug 27;11(9):1256. doi: 10.3390/cancers11091256. Cancers (Basel). 2019. PMID: 31461985 Free PMC article.
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K, Komiyama Y, Higuchi M, Kubota Y, Wang W, Okada M, Enomoto N, Izumi N. Takada H, et al. Among authors: okada m. PLoS One. 2018 Jun 18;13(6):e0198812. doi: 10.1371/journal.pone.0198812. eCollection 2018. PLoS One. 2018. PMID: 29912922 Free PMC article.
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.
Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Wang W, et al. Among authors: okada m. Cancers (Basel). 2019 Oct 9;11(10):1517. doi: 10.3390/cancers11101517. Cancers (Basel). 2019. PMID: 31601010 Free PMC article.
Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M, Gotou T, Kubota Y, Takaura K, Hayashi T, Oh W, Okada M, Enomoto N, Izumi N. Komiyama Y, et al. Among authors: okada m. PLoS One. 2017 Mar 31;12(3):e0174649. doi: 10.1371/journal.pone.0174649. eCollection 2017. PLoS One. 2017. PMID: 28362879 Free PMC article.
Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization.
Yasui Y, Tsuchiya K, Kurosaki M, Takeguchi T, Takeguchi Y, Okada M, Wang W, Kubota Y, Goto T, Komiyama Y, Higuchi M, Takaura K, Hayashi T, Takada H, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Himeno Y, Izumi N. Yasui Y, et al. Among authors: okada m. Hepatol Res. 2018 May;48(6):442-450. doi: 10.1111/hepr.13048. Epub 2018 Feb 9. Hepatol Res. 2018. PMID: 29278654
Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus.
Yasui Y, Kurosaki M, Komiyama Y, Takada H, Tamaki N, Watakabe K, Okada M, Wang W, Shimizu T, Kubota Y, Higuchi M, Takaura K, Tsuchiya K, Nakanishi H, Takahashi Y, Itakura J, Enomoto N, Izumi N. Yasui Y, et al. Among authors: okada m. Hepatol Res. 2018 Dec;48(13):1131-1139. doi: 10.1111/hepr.13233. Epub 2018 Aug 23. Hepatol Res. 2018. PMID: 30030872
Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography.
Higuchi M, Tamaki N, Kurosaki M, Watakabe K, Osawa L, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Higuchi M, et al. Among authors: okada m. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2616-2618. doi: 10.1016/j.cgh.2018.11.046. Epub 2018 Nov 28. Clin Gastroenterol Hepatol. 2019. PMID: 30502507
Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K, Komiyama Y, Higuchi M, Kubota Y, Wang W, Okada M, Shimizu T, Watakabe K, Enomoto N, Izumi N. Takada H, et al. Among authors: okada m. PLoS One. 2019 Feb 15;14(2):e0211122. doi: 10.1371/journal.pone.0211122. eCollection 2019. PLoS One. 2019. PMID: 30768601 Free PMC article.
Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Tamaki N, et al. Among authors: okada m. J Viral Hepat. 2019 Jul;26(7):893-899. doi: 10.1111/jvh.13103. Epub 2019 May 3. J Viral Hepat. 2019. PMID: 30974045
Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Yasui Y, Tsuchiya K, Nakanishi H, Takahashi Y, Watanabe M, Izumi N. Kaneko S, et al. Among authors: okada m. J Gastroenterol Hepatol. 2019 Nov;34(11):2004-2010. doi: 10.1111/jgh.14686. Epub 2019 May 21. J Gastroenterol Hepatol. 2019. PMID: 31017689
6,089 results